Contribute to integrated evidence-generation planning by identifying critical scientific, clinical, and strategic evidence gaps across AD, HS, and early-stage assets, and support studies, analyses, real-world evidence, biomarker/translational research, publications, and other initiatives designed to address them. Develop deep expertise in AD and HS disease biology, patient journeys, current and emerging treatment landscapes, mechanisms of action, clinical endpoints, and unmet needs, while maintaining a forward-looking understanding of innovation across dermatology.